BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)-AKT signal transduction pathway is critical to cell growth and survival. In vitro functional studies indicate that the candidate schizophrenia susceptibility gene DTNBP1 influences AKT signaling to promote neuronal viability. The AKT1 gene has also been implicated in schizophrenia by association studies and decreased protein expression in the brains of schizophrenic patients. METHODS: The association of DTNBP1 in the Irish Study of High Density Schizophrenia Families (ISHDSF) prompted our investigation of AKT1 for association with disease in this sample. Eight single nucleotide polymorphisms spanning AKT1 were analyzed for association with schizophrenia across four definitions of affection and according to Operational Criteria Checklist of Psychotic Illness (OPCRIT) symptom scales. We examined expression of AKT1 messenger RNA from postmortem brain tissue of schizophrenic, bipolar, and control individuals. RESULTS: No single marker showed significant association, but the risk haplotype previously found over-transmitted to Caucasian schizophrenic patients was significantly under-transmitted in the ISHDSF (.01 < p < .05), across all OPCRIT symptom dimensions. Exploratory haplotype analysis confirmed association with schizophrenia toward the 5' end of AKT1 (.008 < p < .049, uncorrected). We found significantly decreased RNA levels in prefrontal cortex of schizophrenic individuals, consistent with reduced AKT1 protein levels reported in schizophrenic brain. CONCLUSIONS: The replication of association of AKT1 gene variants in a further Caucasian family sample adds support for involvement of AKT signaling in schizophrenia, perhaps encompassing a broader clinical phenotype that includes mood dysregulation. We show that AKT signaling might be compromised in schizophrenic and bipolar patients via reduced RNA expression of specific AKT isoforms.
BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)-AKT signal transduction pathway is critical to cell growth and survival. In vitro functional studies indicate that the candidate schizophrenia susceptibility gene DTNBP1 influences AKT signaling to promote neuronal viability. The AKT1 gene has also been implicated in schizophrenia by association studies and decreased protein expression in the brains of schizophrenicpatients. METHODS: The association of DTNBP1 in the Irish Study of High Density Schizophrenia Families (ISHDSF) prompted our investigation of AKT1 for association with disease in this sample. Eight single nucleotide polymorphisms spanning AKT1 were analyzed for association with schizophrenia across four definitions of affection and according to Operational Criteria Checklist of Psychotic Illness (OPCRIT) symptom scales. We examined expression of AKT1 messenger RNA from postmortem brain tissue of schizophrenic, bipolar, and control individuals. RESULTS: No single marker showed significant association, but the risk haplotype previously found over-transmitted to Caucasian schizophrenicpatients was significantly under-transmitted in the ISHDSF (.01 < p < .05), across all OPCRIT symptom dimensions. Exploratory haplotype analysis confirmed association with schizophrenia toward the 5' end of AKT1 (.008 < p < .049, uncorrected). We found significantly decreased RNA levels in prefrontal cortex of schizophrenic individuals, consistent with reduced AKT1 protein levels reported in schizophrenic brain. CONCLUSIONS: The replication of association of AKT1 gene variants in a further Caucasian family sample adds support for involvement of AKT signaling in schizophrenia, perhaps encompassing a broader clinical phenotype that includes mood dysregulation. We show that AKT signaling might be compromised in schizophrenic and bipolarpatients via reduced RNA expression of specific AKT isoforms.
Authors: Robin M Murray; Pak Sham; Jim Van Os; Jolanta Zanelli; Mary Cannon; Colm McDonald Journal: Schizophr Res Date: 2004-12-01 Impact factor: 4.939
Authors: Jean-Martin Beaulieu; Tatyana D Sotnikova; Wei-Dong Yao; Lisa Kockeritz; James R Woodgett; Raul R Gainetdinov; Marc G Caron Journal: Proc Natl Acad Sci U S A Date: 2004-03-24 Impact factor: 11.205
Authors: E J C G van den Oord; P F Sullivan; Y Jiang; D Walsh; F A O'Neill; K S Kendler; B P Riley Journal: Mol Psychiatry Date: 2003-05 Impact factor: 15.992
Authors: Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli Journal: J Neurosci Date: 2010-08-25 Impact factor: 6.167
Authors: Rodrigo Machado-Vieira; Marcus V Zanetti; Antonio L Teixeira; Miyuki Uno; Leandro L Valiengo; Marcio G Soeiro-de-Souza; Sueli M Oba-Shinjo; Rafael T de Sousa; Carlos A Zarate; Wagner F Gattaz; Suely K N Marie Journal: Eur Neuropsychopharmacol Date: 2015-02-16 Impact factor: 4.600
Authors: Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino Journal: Proc Natl Acad Sci U S A Date: 2010-12-27 Impact factor: 11.205
Authors: Jennifer A McKenzie; Sarah Witkowski; Andrew T Ludlow; Stephen M Roth; James M Hagberg Journal: Exp Physiol Date: 2010-11-19 Impact factor: 2.969
Authors: Jeremy M Veenstra-Vanderweele; Aurelio Galli; Christine Saunders; Michael Siuta; Sabrina D Robertson; Adeola R Davis; Jennifer Sauer; Heinrich J G Matthies; Paul J Gresch; David Airey; Craig W Lindsley; John A Schetz; Kevin D Niswender Journal: Neurochem Int Date: 2013-09-30 Impact factor: 3.921
Authors: Xiaoduo Fan; Emily Liu; Oliver Freudenreich; Paul Copeland; Douglas Hayden; Musie Ghebremichael; Bruce Cohen; Dost Ongur; Donald C Goff; David C Henderson Journal: J Clin Psychopharmacol Date: 2013-04 Impact factor: 3.153
Authors: Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin Journal: Pharmacogenomics J Date: 2015-08-18 Impact factor: 3.550